Compare VINP & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VINP | CMPS |
|---|---|---|
| Founded | 2009 | 2020 |
| Country | Brazil | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 702.6M | 778.7M |
| IPO Year | 2020 | 2020 |
| Metric | VINP | CMPS |
|---|---|---|
| Price | $10.25 | $6.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $14.00 | ★ $27.14 |
| AVG Volume (30 Days) | 73.2K | ★ 4.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.16% | N/A |
| EPS Growth | N/A | ★ 0.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.80 | N/A |
| Revenue Next Year | $13.97 | N/A |
| P/E Ratio | $24.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.66 | $2.25 |
| 52 Week High | $13.61 | $8.90 |
| Indicator | VINP | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 23.09 | 43.07 |
| Support Level | $9.25 | $5.95 |
| Resistance Level | $10.87 | $7.02 |
| Average True Range (ATR) | 0.60 | 0.50 |
| MACD | -0.18 | -0.09 |
| Stochastic Oscillator | 0.19 | 3.93 |
Vinci Compass Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Equity, Equities, Real Assets, Credit, Global IP&S, and Corporate Advisory. The company's majority of its revenue comes from the Private Equity segment, which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.